

Claims

1. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with elevated blood uric acid levels.
2. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof as defined in claim 1 wherein the disease associated with elevated blood uric acid levels is hyperuricemia.
3. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof as defined in claim 1 wherein the disease associated with elevated blood uric acid levels is gout.
4. Use of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease associated with elevated blood uric acid levels.
5. The use according to claim 4 wherein the disease associated with elevated blood uric acid levels is hyperuricemia.
6. The use according to claim 4 wherein the disease associated with elevated blood uric acid levels is gout.
- ~~7. A method of treating a disease associated with elevated blood uric acid levels comprising the administration of a therapeutically effective amount of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof to a subject in need of such treatment.~~
87. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof

in combination with one or more additional pharmaceutically active agents for the treatment of a disease associated with elevated blood uric acid levels.

98. The combination according to claim 87 wherein the one or more additional pharmaceutically active agents is/are selected from:

- an anti-inflammatory drug such as an NSAID (e.g. celecoxib), colchicine or a steroid;
- a xanthine oxidase inhibitor (e.g. allopurinol, febuxostat or tisopurine) or a purine nucleoside phosphorylase (PNP) inhibitor (e.g. ulodesine);
- a uricase (e.g. pegloticase or rasburicase); or a
- a uricosuric, such as an agent that inhibits the transporters responsible for renal reabsorption of uric acid back into the blood, such as benzbromarone, isobromindione, probenecid and sulphinpyrazone, or a URAT-1 inhibitor (e.g. benzbromarone).

109. The combination according to any one of claims 87 or 98 wherein the disease associated with elevated blood uric acid levels is hyperuricemia.

110. The method according to any one of claims 87 or 98 wherein the disease associated with elevated blood uric acid levels is gout.

1211. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate.

1312. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to claim 1211 which is a crystalline solid.

1413. The crystalline solid according to claim 1312 characterised by a Powder X-Ray Diffraction pattern (PXRD) pattern which shows any of three, four, five or six characteristic two-theta (2θ) peaks selected from the group consisting of 9.0, 9.3, 10.0, 10.7, 11.6, 12.5, 12.9, 13.2, 13.8, 14.4, 16.0, 16.6, 17.5, 17.8, 18.1,

21.4 and 23.4° (+/- 0.2° 2θ) by using CuKalpha1 X-ray radiation (wavelength = 1.5406 Å).

4514. A pharmaceutical composition comprising 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to any one of claims 4211 to 4413 and a pharmaceutically acceptable carrier.

4615. The pharmaceutically composition according to claim 4514 which is in the form of a tablet or capsule.

4716. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to any one of claims 4211 to 4413 for use as a medicament.

4817. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to claim 4716 for use in the treatment of a disorder for which a Na_v1.7 inhibitor is indicated.

4918. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to claim 4817 wherein the disorder for which a Na_v1.7 inhibitor is indicated is pain, preferably neuropathic, nociceptive or inflammatory pain.

2019. 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to claim 4716 for use in the treatment of a disease associated with elevated blood uric acid levels.

2420. Use of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to any one of claims 4211 to 4413 for the manufacture of a medicament for the treatment of pain, preferably neuropathic, nociceptive or inflammatory pain.

2221. Use of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to any one of claims 4211 to 4413 for the manufacture of a medicament for the treatment of a disease associated with elevated blood uric acid levels.

~~23. A method of treating pain, preferably neuropathic, nociceptive or inflammatory pain, comprising the administration of a therapeutically effective amount of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to any one of claims 12 to 14 to a subject in need of such treatment.~~

~~24. A method of treating a disease associated with elevated blood uric acid levels comprising the administration of a therapeutically effective amount of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide tosylate according to any one of claims 12 to 14 to a subject in need of such treatment.~~